425 related articles for article (PubMed ID: 30235988)
1. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
[TBL] [Abstract][Full Text] [Related]
2. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.
Safer JD; Cohen RN; Hollenberg AN; Wondisford FE
J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773
[TBL] [Abstract][Full Text] [Related]
3. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators.
Tagami T; Gu WX; Peairs PT; West BL; Jameson JL
Mol Endocrinol; 1998 Dec; 12(12):1888-902. PubMed ID: 9849963
[TBL] [Abstract][Full Text] [Related]
4. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor.
Jeyakumar M; Webb P; Baxter JD; Scanlan TS; Katzenellenbogen JA
Biochemistry; 2008 Jul; 47(28):7465-76. PubMed ID: 18558711
[TBL] [Abstract][Full Text] [Related]
5. Thyroid hormone receptor-specific interactions with steroid receptor coactivator-1 in the pituitary.
Sadow PM; Koo E; Chassande O; Gauthier K; Samarut J; Xu J; O'Malley BW; Seo H; Murata Y; Weiss RE
Mol Endocrinol; 2003 May; 17(5):882-94. PubMed ID: 12576486
[TBL] [Abstract][Full Text] [Related]
6. Tetrabromobisphenol-A disrupts thyroid hormone receptor alpha function in vitro: use of fluorescence polarization to assay corepressor and coactivator peptide binding.
Lévy-Bimbot M; Major G; Courilleau D; Blondeau JP; Lévi Y
Chemosphere; 2012 May; 87(7):782-8. PubMed ID: 22277881
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors.
Yoh SM; Chatterjee VK; Privalsky ML
Mol Endocrinol; 1997 Apr; 11(4):470-80. PubMed ID: 9092799
[TBL] [Abstract][Full Text] [Related]
8. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT.
Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H
J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777
[TBL] [Abstract][Full Text] [Related]
9. The in vivo role of nuclear receptor corepressors in thyroid hormone action.
Astapova I; Hollenberg AN
Biochim Biophys Acta; 2013 Jul; 1830(7):3876-81. PubMed ID: 22801336
[TBL] [Abstract][Full Text] [Related]
10. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
[TBL] [Abstract][Full Text] [Related]
11. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.
Collingwood TN; Wagner R; Matthews CH; Clifton-Bligh RJ; Gurnell M; Rajanayagam O; Agostini M; Fletterick RJ; Beck-Peccoz P; Reinhardt W; Binder G; Ranke MB; Hermus A; Hesch RD; Lazarus J; Newrick P; Parfitt V; Raggatt P; de Zegher F; Chatterjee VK
EMBO J; 1998 Aug; 17(16):4760-70. PubMed ID: 9707435
[TBL] [Abstract][Full Text] [Related]
12. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains.
Cohen RN; Brzostek S; Kim B; Chorev M; Wondisford FE; Hollenberg AN
Mol Endocrinol; 2001 Jul; 15(7):1049-61. PubMed ID: 11435607
[TBL] [Abstract][Full Text] [Related]
13. Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors.
Vella KR; Ramadoss P; Costa-E-Sousa RH; Astapova I; Ye FD; Holtz KA; Harris JC; Hollenberg AN
Mol Cell Biol; 2014 May; 34(9):1564-75. PubMed ID: 24550004
[TBL] [Abstract][Full Text] [Related]
14. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
Tagami T; Jameson JL
Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
[TBL] [Abstract][Full Text] [Related]
15. Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor.
Yoh SM; Privalsky ML
Mol Cell Endocrinol; 2000 Jan; 159(1-2):109-24. PubMed ID: 10687857
[TBL] [Abstract][Full Text] [Related]
16. RXR agonist modulates TR: corepressor dissociation upon 9-cis retinoic acid treatment.
Fattori J; Campos JL; Doratioto TR; Assis LM; Vitorino MT; Polikarpov I; Xavier-Neto J; Figueira AC
Mol Endocrinol; 2015 Feb; 29(2):258-73. PubMed ID: 25541638
[TBL] [Abstract][Full Text] [Related]
17. Determination of nuclear receptor corepressor interactions with the thyroid hormone receptor.
Makowski A; Brzostek S; Cohen RN; Hollenberg AN
Mol Endocrinol; 2003 Feb; 17(2):273-86. PubMed ID: 12554754
[TBL] [Abstract][Full Text] [Related]
18. Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor beta gene.
Pohlenz J; Weiss RE; Macchia PE; Pannain S; Lau IT; Ho H; Refetoff S
J Clin Endocrinol Metab; 1999 Nov; 84(11):3919-28. PubMed ID: 10566629
[TBL] [Abstract][Full Text] [Related]
19. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
Suzuki H; Zhang XY; Forrest D; Willingham MC; Cheng SY
Mol Endocrinol; 2003 May; 17(5):895-907. PubMed ID: 12576488
[TBL] [Abstract][Full Text] [Related]
20. A de novo mutation in an already mutant nucleotide of the thyroid hormone receptor beta gene perpetuates resistance to thyroid hormone.
Lado-Abeal J; Dumitrescu AM; Liao XH; Cohen RN; Pohlenz J; Weiss RE; Lebrethon MC; Verloes A; Refetoff S
J Clin Endocrinol Metab; 2005 Mar; 90(3):1760-7. PubMed ID: 15598685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
